In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endosense: Growing Up Fast in AF

Executive Summary

Hoping to succeed in the elusive field of atrial fibrillation, Endosense is taking an anti-start-up strategy: focusing more on later-stage commercialization and market launch and less on technology vetting.

You may also be interested in...



Endosense: Facing Technology and Financing Challenges in AF

Endosense is beginning to establish itself in the tough market of atrial fibrillation with a catheter that stresses an attribute that no one has featured yet: force sensing in delivering energy. Proving the clinical value of force-sensing will be difficult enough, but Endosense faced an even greater challenge in 2009 when its long-time backer, 3i, decided it wanted to exit device venture investing and divest its stake in the company.

Endosense: Facing Technology and Financing Challenges in AF

Endosense is beginning to establish itself in the tough market of atrial fibrillation with a catheter that stresses an attribute that no one has featured yet: force sensing in delivering energy. Proving the clinical value of force-sensing will be difficult enough, but Endosense faced an even greater challenge in 2009 when its long-time backer, 3i, decided it wanted to exit device venture investing and divest its stake in the company.

Advanced Cardiac Therapeutics Inc.

For more than 20 years, cardiac ablation catheter development has focused on two major areas: three-dimensional mapping systems to determine a specific patient's heart dimensions to help map arrhythmias and guide catheters, and mechanisms for catheter positioning and steerability. Little attention has been devoted to ablation lesion success and safety assessment. Advanced Cardiac Therapeutics Inc. aims to fill this gap with its intelligent, in-tissue, temperature-sensing irrigated ablation catheter. The device features a chip-based radiometry system to provide physicians with real-time in-tissue temperature when performing irrigated cardiac ablations.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel